Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2018 Feb 14

PMID 29436198

Citations 7

Authors

Jung Ran Choi

Jang Young Kim

Il Hwan Park

Ji Hye Huh

Ki Woo Kim

Seung Kuy Cha

Kyu Sang Park

Joon Hyung Sohn

Jong Taek Park

Sang Baek Koh

Affiliations

Soon will be listed here.

Abstract

Purpose: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a potential marker for the early identification of metabolic syndrome (MetS), we investigated the association between serum FGF21 level and the development of MetS in a population-based prospective study.

Materials And Methods: We conducted a prospective study of 221 randomly sampled adults without MetS from a general population-based cohort study who were examined from 2005-2008 (baseline) and from 2008-2011 (follow-up). Baseline serum FGF21 levels were analyzed using enzyme-linked immunosorbent assay.

Results: During the average 2.8-year follow-up period, 82 participants (36.6%) developed new-onset MetS. Serum FGF21 levels were significantly higher in patients with new-onset MetS than in those without MetS (209.56±226.80 vs. 110.09±81.10, p<0.01). In multivariate adjusted models, the odds for MetS development were greater in patients with serum FGF21 levels in the highest quartile, compared to those in the lowest quartile (3.84, 95% confidence interval: 1.59-9.28).

Conclusion: Serum FGF21 level was an independent predictor for new-onset MetS in a population-based prospective study.

Citing Articles

The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review.

Negroiu C, Tudorascu R, Bezna M, Ungureanu A, Hontaru S, Danoiu S Rom J Morphol Embryol. 2024; 65(2):159-172.

PMID: 39020530 PMC: 11384831. DOI: 10.47162/RJME.65.2.02.

The elevation of fibroblast growth factor 21 is associated with generalized periodontitis in patients with treated metabolic syndrome.

Sawangpanyangkura T, Bandhaya P, Montreekachon P, Leewananthawet A, Phrommintikul A, Chattipakorn N BMC Oral Health. 2022; 22(1):570.

PMID: 36474191 PMC: 9724428. DOI: 10.1186/s12903-022-02533-3.

Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial.

Chang J, Namkung J Int J Environ Res Public Health. 2021; 18(5).

PMID: 33668309 PMC: 7956208. DOI: 10.3390/ijerph18052242.

Dietary Protein to Carbohydrate Ratio and Incidence of Metabolic Syndrome in Korean Adults Based on a Long-Term Prospective Community-Based Cohort.

Paik J, Park M, Shin J, Jang S, Shin J Nutrients. 2020; 12(11).

PMID: 33114605 PMC: 7693766. DOI: 10.3390/nu12113274.

Meta-analysis of genome-wide association studies for loin muscle area and loin muscle depth in two Duroc pig populations.

Zhuang Z, Li S, Ding R, Yang M, Zheng E, Yang H PLoS One. 2019; 14(6):e0218263.

PMID: 31188900 PMC: 6561594. DOI: 10.1371/journal.pone.0218263.

References

Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer A, Mohlig M, Mai K . Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2012; 36(1):145-9. PMC: 3526237. DOI: 10.2337/dc12-0703. View

Lim S, Shin H, Song J, Kwak S, Kang S, Yoon J . Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011; 34(6):1323-8. PMC: 3114326. DOI: 10.2337/dc10-2109. View

Zhang F, Yu L, Lin X, Cheng P, He L, Li X . Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Mol Endocrinol. 2015; 29(10):1400-13. PMC: 4588730. DOI: 10.1210/me.2015-1155. View

Lundasen T, Hunt M, Nilsson L, Sanyal S, Angelin B, Alexson S . PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007; 360(2):437-40. DOI: 10.1016/j.bbrc.2007.06.068. View

Matuszek B, Lenart-Lipinska M, Duma D, Solski J, Nowakowski A . Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol Pol. 2010; 61(1):50-4. View

Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S . Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2011; 5(12):e15534. PMC: 3012070. DOI: 10.1371/journal.pone.0015534. View

Zhang X, Yeung D, Karpisek M, Stejskal D, Zhou Z, Liu F . Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5):1246-53. DOI: 10.2337/db07-1476. View

Dushay J, Chui P, Gopalakrishnan G, Varela-Rey M, Crawley M, Fisher F . Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139(2):456-63. PMC: 4862867. DOI: 10.1053/j.gastro.2010.04.054. View

Zhou Z, Hu D, Chen J . Association between obesity indices and blood pressure or hypertension: which index is the best?. Public Health Nutr. 2008; 12(8):1061-71. DOI: 10.1017/S1368980008003601. View

10.

Badman M, Pissios P, Kennedy A, Koukos G, Flier J, Maratos-Flier E . Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007; 5(6):426-37. DOI: 10.1016/j.cmet.2007.05.002. View

11.

Fisher F, Chui P, Antonellis P, Bina H, Kharitonenkov A, Flier J . Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010; 59(11):2781-9. PMC: 2963536. DOI: 10.2337/db10-0193. View

12.

Ong K, Rye K, OConnell R, Jenkins A, Brown C, Xu A . Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(12):4701-8. DOI: 10.1210/jc.2012-2267. View

13.

Bagheri L, Hami M, Mojahedi M, Ghorban Sabbagh M, Ayatollahi H . Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients. J Renal Inj Prev. 2016; 5(2):79-84. PMC: 4962674. DOI: 10.15171/jrip.2016.17. View

14.

Lee S, Park H, Kim D, Han J, Kim S, Cho G . Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2006; 75(1):72-80. DOI: 10.1016/j.diabres.2006.04.013. View

15.

Moyers J, Shiyanova T, Mehrbod F, Dunbar J, Noblitt T, Otto K . Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol. 2006; 210(1):1-6. DOI: 10.1002/jcp.20847. View

16.

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M . Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. PMC: 3766150. DOI: 10.1186/1475-2840-12-124. View

17.

Kim S, Kim K, Kim H, Kim M, Back S, Konishi M . Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia. 2014; 58(4):809-18. DOI: 10.1007/s00125-014-3475-6. View

18.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

19.

Nestel P, Lyu R, Low L, Sheu W, Nitiyanant W, Saito I . Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr. 2007; 16(2):362-7. View

20.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View